Sep 14, 2020
What a difference a few months can make – especially during a pandemic. Heading into 2020, biopharma looked like it would be typecast in its typical election year role: the big business scapegoat for everything that’s wrong in health care. There had been the usual big...
Jul 22, 2020
Locust Walk is partnering with Applied Molecular Transport, Forma Therapeutics, and Goodwin for a live panel on Thursday, July 23rd from 1-2 pm EST entitled “The Unexpected IPO Boom for Biopharma in Q2.” CLICK HERE TO REGISTER Q2 saw a boom in IPOs, while...
Jun 8, 2020
Danforth Advisors, Locust Walk, and Mintz joined on Thursday, June 11th from 2-3pm EST for the panel, “Accessing Capital in the Time of COVID: Challenges, Opportunities, and Best Practices.” During the hour, the panel discussed How COVID-19 impacted the...
Jul 30, 2019
Overview Biotech companies are attracted to licensing deals for a variety of important reasons: 1) to provide an alternative source of capital from the licensee to fund R&D and commercial operations including, but not limited to, advancement of the asset(s) in...
May 20, 2019
Brian Coleman, Locust Walk’s Managing Director, Global Head of Financing and Sales will be moderating the panel, Drawing Your Financing Roadmap, at BioEquity Europe: Faced with an expanding range of financing options, early stage biotech executives must figure...
Nov 2, 2017
Besides calling the Ghostbusters, how does one catch a ghost? That is the question asked by most life science companies trying to raise capital from family offices, which we define as a non-institutional investor capable of investing $1M or more into an individual...
